Thalys Medical Technology Group Inc. (603716.SS)
CNY 9.69
(-3.77%)
CNY 9.69
(-3.77%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 772.55 Million CNY | -25.81% |
| 2022 | 1.04 Billion CNY | -9.33% |
| 2021 | 1.14 Billion CNY | 55.78% |
| 2020 | 737.18 Million CNY | 97.42% |
| 2019 | 373.4 Million CNY | 3097.71% |
| 2018 | -12.45 Million CNY | -108.77% |
| 2017 | 142 Million CNY | 176.34% |
| 2016 | -186 Million CNY | -781.4% |
| 2015 | 27.29 Million CNY | 56.96% |
| 2014 | 17.39 Million CNY | 5660.76% |
| 2013 | -312.75 Thousand CNY | 95.12% |
| 2012 | -6.4 Million CNY | 85.55% |
| 2011 | -44.31 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 885.79 Million CNY | -2.18% |
| 2024 Q3 | 846.94 Million CNY | -2.92% |
| 2024 Q1 | 905.56 Million CNY | 17.22% |
| 2023 Q1 | 1.02 Billion CNY | -1.4% |
| 2023 FY | 772.55 Million CNY | -25.81% |
| 2023 Q4 | 772.55 Million CNY | -20.0% |
| 2023 Q3 | 965.7 Million CNY | 2.53% |
| 2023 Q2 | 941.91 Million CNY | -8.26% |
| 2022 Q4 | 1.04 Billion CNY | -14.7% |
| 2022 Q3 | 1.22 Billion CNY | -9.59% |
| 2022 Q1 | 1.12 Billion CNY | -1.89% |
| 2022 Q2 | 1.35 Billion CNY | 19.84% |
| 2022 FY | 1.04 Billion CNY | -9.33% |
| 2021 Q2 | 1.05 Billion CNY | 30.52% |
| 2021 Q3 | 974.52 Million CNY | -7.42% |
| 2021 Q4 | 1.14 Billion CNY | 17.84% |
| 2021 Q1 | 806.5 Million CNY | 9.4% |
| 2021 FY | 1.14 Billion CNY | 55.78% |
| 2020 Q1 | 458.73 Million CNY | 22.85% |
| 2020 FY | 737.18 Million CNY | 97.42% |
| 2020 Q3 | 626.75 Million CNY | 6.29% |
| 2020 Q2 | 589.63 Million CNY | 28.53% |
| 2020 Q4 | 737.18 Million CNY | 17.62% |
| 2019 FY | 373.4 Million CNY | 3097.71% |
| 2019 Q4 | 373.4 Million CNY | 47.31% |
| 2019 Q3 | 253.47 Million CNY | -2.02% |
| 2019 Q2 | 258.69 Million CNY | 101.56% |
| 2019 Q1 | 128.34 Million CNY | 1130.37% |
| 2018 Q2 | -207.13 Million CNY | -174.94% |
| 2018 Q1 | 276.38 Million CNY | 94.63% |
| 2018 Q3 | -109.21 Million CNY | 47.27% |
| 2018 FY | -12.45 Million CNY | -108.77% |
| 2018 Q4 | -12.45 Million CNY | 88.59% |
| 2017 Q3 | 94.46 Million CNY | 433.86% |
| 2017 FY | 142 Million CNY | 176.34% |
| 2017 Q4 | 142 Million CNY | 50.33% |
| 2017 Q2 | -28.29 Million CNY | 74.29% |
| 2017 Q1 | -110.05 Million CNY | 40.83% |
| 2016 Q1 | 96.71 Million CNY | 254.31% |
| 2016 FY | -186 Million CNY | -781.4% |
| 2016 Q4 | -186 Million CNY | -257.37% |
| 2016 Q2 | 59.89 Million CNY | -38.07% |
| 2016 Q3 | 118.2 Million CNY | 97.34% |
| 2015 Q4 | 27.29 Million CNY | 0.0% |
| 2015 FY | 27.29 Million CNY | 56.96% |
| 2014 FY | 17.39 Million CNY | 5660.76% |
| 2013 FY | -312.75 Thousand CNY | 95.12% |
| 2012 FY | -6.4 Million CNY | 85.55% |
| 2011 FY | -44.31 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 5.96 Billion CNY | 87.051% |
| Joinn Laboratories(China)Co.,Ltd. | -2.77 Billion CNY | 127.818% |
| WuXi AppTec Co., Ltd. | -4.24 Billion CNY | 118.192% |
| Autobio Diagnostics Co., Ltd. | -448.29 Million CNY | 272.332% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | -1.87 Billion CNY | 141.122% |
| Chemclin Diagnostics Co., Ltd. | -214.05 Million CNY | 460.914% |